BioVie Inc. is hosting a conference call and webcast to discuss topline results from its Phase 2 ADDRESS-LC trial evaluating its investigational drug candidate bezisterim, an oral drug that crosses the blood-brain barrier and is believed to reduce inflammation and improve insulin sensitivity, in Long COVID.

Michael Peluso, MD, MHS, Associate Professor of Medicine, University of California, San Francisco, and an investigator in the trial, and Ezra Spier, Long COVID patient advocate and a patient advisor on the ADDRESS-LC trial, will be guest speakers at the event.

A live Q&A session with management will follow the presentation.